Investigation Launched into FONAR Corporation's Board Actions

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 6d ago

0mins

FONR-0.11%

Should l Buy FONR?

Source: PRnewswire

Investigation Initiated: Levi & Korsinsky, LLP has officially launched an investigation into potential breaches of fiduciary duty by the board of FONAR Corporation (NASDAQ:FONR), focusing on a management-led take-private merger approved in December 2025.
Merger Scrutiny: The investigation examines whether the management-led merger involved conflicts of interest that could adversely affect shareholder rights, potentially leading to significant implications for the company's governance structure.
Legal Expertise: Levi & Korsinsky is a nationally recognized law firm specializing in securities litigation, having recovered hundreds of millions for investors, showcasing its expertise in handling such cases effectively.
Shareholder Rights Protection: This investigation aims to safeguard the interests of FONAR shareholders, underscoring the importance of governance transparency and potentially prompting stricter regulatory measures in the future.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy FONR?" and start using high-conviction signals backed by rigorous historical data.

FONR

$18.54+Infinity%1D

Analyst Views on FONR

About FONR

FONAR Corporation is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (MRI) for the detection and diagnosis of human diseases. The Company conducts its business in two segments: medical equipment and physician management and diagnostic services. Its medical equipment segment is conducted directly through the Company. Its physician management and diagnostic services segment is conducted through its subsidiary, Health Management Corporation of America (HMCA). Its signature product is the FONAR UPRIGHT Multi-Position MRI (STAND-UP MRI). HMCA provides management services, administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, hiring, maintenance service, and clerical and other non-medical personnel to medical providers engaged in diagnostic imaging. HMCA owns and operates six diagnostic imaging facilities in Florida.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Investor Rights Law Firm Investigates Multiple Companies

6 days agoGlobenewswire

Legal Investigation Initiated: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) regarding its sale to GSK plc for $58.00 per share, potentially violating fiduciary duties to shareholders and impacting shareholder rights.
Shareholder Rights Protection: The transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation involves $374.00 in cash or 3.8721 shares of Boston Scientific common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
Cash and Stock Transaction: Calavo Growers, Inc. (NASDAQ: CVGW) is selling to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission stock per share, prompting Halper Sadeh LLC to assess the potential impact of this transaction on shareholders.
Management Transaction Review: FONAR Corporation (NASDAQ: FONR) is involved in a transaction with its CEO and certain executives for $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC possibly advocating for enhanced shareholder rights.

Investigation Alerts for Multiple Company Mergers

6 days agoGlobenewswire

RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.